Cost-Effectiveness of Ibrutinib for Chronic Lymphocytic Leukemia Treatment in India: Is Evidence Really at Crossroads?
Abstract
In recent years, newer drugs, such as ibrutinib, have shown promising
improvements in the survival of patients with chronic lymphocytic
leukemia (CLL). Despite their effectiveness, concerns about their cost
have arisen, prompting the need for an evaluation of their
cost-effectiveness. However, recent assessments of ibrutinib’s
cost-effectiveness for treating CLL in India reveal divergent
conclusions. The discord centers on divergent cost-effectiveness
thresholds, comparator regimens, cost calculations, and outcome
valuation approaches. Such discrepancies affect public health decisions
and patient care. The recommendation calls for adherence to
methodological guidelines by future studies, fostering consistent
findings to empower policy makers and clinicians in leveraging economic
evidence for informed decision making in CLL treatment strategies.
Authors
Nidhi Gupta Gaurav Jyani